Less common genotype variants of TP53 polymorphisms are associated with poor outcome in adult patients with adrenocortical carcinoma

European Journal of Endocrinology

Volumn 170, Issue 5, 2014, Pages 707-717

  Heinze, Britta ^a   Herrmann, Leonie J M ^a   Fassnacht, Martin ^a,b   Ronchi, Cristina L ^a   Willenberg, Holger S ^c   Quinkler, Marcus ^d   Reisch, Nicole ^b   Zink, Martina ^a   Allolio, Bruno ^a   Hahner, Stefanie ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Medical Faculty   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CAUCASIAN; CONTROLLED STUDY; DNA EXTRACTION; EXON; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE FUNCTION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TP53 GENE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; GERMANY; HUMANS; INTRONS; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; POLYMORPHISM, GENETIC; PROGNOSIS; REGISTRIES; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84899719233     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0788     Document Type: Article

References (43)

1. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P & Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human Mutation 2007 28 622-629. (doi:10.1002/humu.20495
2. Whibley C, Pharoah P & Hollstein M. p53 polymorphisms: cancer implications. Nature Reviews. Cancer 2009 9 95-107. (doi:10.1038/nrc2584
3. Levine AJ, Hu W & Feng Z. The P53 pathway: what questions remain to be explored? Cell Death and Differentiation 2006 13 1027-1036. (doi:10.1038/sj.cdd.4401910
4. Runnebaum IB, Tong XW, König R, Zhao H, Körner K, Atkinson EN, Kreienberg R, Kieback DG & Hong Z [corrected to Zhao H]. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet 1995 345 994. (doi:10.1016/S0140-6736(95)90745-9
5. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF & Spitz MR. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. Journal of the National Cancer Institute 2002 94 681-690. (doi:10.1093/jnci/94.9.681
6. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, Hall J, Guino E, Peinado MA, Capella G et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004 23 1954-1956. England. (doi:10.1038/sj.onc.1207305
7. Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R & Schmitt F. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 2008 8 32. (doi:10.1186/1471-2407-8-32
8. Pleasants L & Hansen M. Identification of a polymorphism in intron 2 of the p53 gene. Human Genetics 1994 93 607-608. (doi:10.1007/BF00202835
9. Høgdall EV, Kjaer SK, Glud E, Christensen L, Blaakaer J, Vuust J, Bock JE, Norgaard-Pedersen B & Hogdall CK. Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study. Anticancer Research 2003 23 3397-3404.
10. Pietsch EC, Humbey O & Murphy ME. Polymorphisms in the p53 pathway. Oncogene 2006 25 1602-1611. (doi:10.1038/sj.onc.1209367
11. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A & Beckman L. Is p53 polymorphism maintained by natural selection? Human Heredity 1994 44 266-270. (doi:10.1159/000154228
12. Sjalander A, Birgander R, Saha N, Beckman L & Beckman G. p53 polymorphisms and haplotypes show distinct differences between major ethnic groups. Human Heredity 1996 46 41-48. (doi:10.1159/000154324
13. Dumont P, Leu JI, Della Pietra AC III, George DL & Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genetics 2003 33 357-365. United States. (doi:10.1038/ng1093
14. Bergamaschi D, Samuels Y, Sullivan A, ZvelebilM, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, GascoMet al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nature Genetics 2006 38 1133-1141. (doi:10.1038/ng1879
15. Hrstka R, Beranek M, Klocova K, Nenutil R & Vojtesek B. Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer. Oncology Reports 2009 22 1205-1211.
16. Wang-Gohrke S, Rebbeck TR, Besenfelder W, Kreienberg R & Runnebaum IB. p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Research 1998 18 2095-2099.
17. Kawajiri K, Nakachi K, Imai K, Watanabe J & Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993 14 1085-1089. (doi:10.1093/carcin/14.6.1085
18. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S & Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 1996 17 261-264. (doi:10.1093/carcin/17.2.261
19. Ignaszak-Szczepaniak M, Horst-Sikorska W, Sawicka J, Kaczmarek M & Slomski R. The TP53 codon 72 polymorphism and predisposition to adrenocortical cancer in Polish patients. Oncology Reports 2006 16 65-71.
20. Osorio A, Martinez-Delgado B, Pollan M, Cuadros M, Urioste M, Torrenteras C, Melchor L, Diez O, De La Hoya M, Velasco E et al. A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers. Human Mutation 2006 27 242-248. (doi:10.1002/humu.20283
21. Boldrini L, Gisfredi S, Ursino S, LucchiM, Greco G, Mussi A, Donati V & Fontanini G. Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis. Cancer Investigation 2008 26 168-172. United States. (doi:10.1080/07357900701788023
22. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, Van de Poll-Franse LV & Haak HR. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. European Journal of Cancer 2013 49 2579-2586. (doi:10.1016/j.ejca.2013.02.034
23. Kebebew E, Reiff E, Duh QY, Clark OH & McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World Journal of Surgery 2006 30 872-878. (doi:10.1007/s00268-005-0329-x
24. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009 115 243-250. (doi:10.1002/cncr.24030
25. Assié G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli JP, Dromain C, Bertagna X et al. Prognostic parameters of metastatic adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2007 92 148-154. (doi:10.1210/jc.2006-0706
26. Miller BS, Gauger PG, Hammer GD, Giordano TJ & Doherty GM. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbeck's Archives of Surgery 2010 395 955-961. (doi:10.1007/s00423-010-0698-y
27. Bourdeau I, MacKenzie-Feder J & Lacroix A. Recent advances in adrenocortical carcinoma in adults. Current Opinion in Endocrinology, Diabetes, and Obesity 2013 20 192-197. (doi:10.1097/MED. 0b013e3283602274
28. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X & Bertherat J. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisolsecreting tumors in a series of 202 consecutive patients. Journal of Clinical Endocrinology and Metabolism 2006 91 2650-2655. (doi:10.1210/jc.2005-2730
29. Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocrine-Related Cancer 2005 12 657-666. England. (doi:10.1677/erc.1.01025
30. Varley JM, Chapman P, McGown G, Thorncroft M, White GR, Greaves MJ, Scott D, Spreadborough A, Tricker KJ, Birch JM et al. Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family. Oncogene 1998 16 3291-3298. (doi:10.1038/sj.onc.1201878
31. Herrmann LJ, Heinze B, Fassnacht M, Willenberg HS, Quinkler M, Reisch N, Zink M, Allolio B & Hahner S. TP53 germline mutations in adult patients with adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2012 97 E476-E485. (doi:10.1210/jc.2011-1982
32. Koschker AC, Fassnacht M, Hahner S, Weismann D & Allolio B. Adrenocortical carcinoma - improving patient care by establishing new structures. Experimental and Clinical Endocrinology & Diabetes 2006 114 45-51. (doi:10.1055/s-2006-923808
33. Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, Langer P, Mussack T, Nies C, Riedmiller H et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. European Urology 2010 58 609-615. (doi:10.1016/j.eururo.2010.06.024
34. Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, Führer D, Jurowich C, Quinkler M, Petersenn S et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. Journal of Clinical Endocrinology and Metabolism 2010 95 4925-4932. (doi:10.1210/jc.2010-0803
35. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. American Journal of Surgical Pathology 1984 8 163-169. (doi:10.1097/00000478-198403000-00001
36. De Feo E, Persiani R, La Greca A, Amore R, Arzani D, Rausei S, D'Ugo D, Magistrelli P, van Duijn C, Ricciardi G et al. A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. Mutation Research 2009 675 60-65. (doi:10.1016/j.mrgentox.2009.02.009
37. Tan X, Nieters A, Hoffmeister M, Beckmann L, Brenner H & Chang-Claude J. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene- environment interaction? Pharmacogenetics and Genomics 2007 17 639-645. (doi:10.1097/FPC.0b013e3280d5121c
38. Rogler A, Rogenhofer M, Borchardt A, Lunz JC, Knoell A, Hofstaedter F, Tannapfel A, Wieland W, Hartmann A & Stoehr R. P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: association between disease onset and proline genotype. Pathobiology 2011 78 193-200. (doi:10.1159/000326767
39. Chen X, Liu F, Li B, Wei YG, Yan LN & Wen TF. p53 codon 72 polymorphism and liver cancer susceptibility: a meta-analysis of epidemiologic studies. World Journal of Gastroenterology 2011 17 1211-1218. (doi:10.3748/wjg.v17.i9.1211
40. Ragazzon B, Libe R, Gaujoux S, Assie G, Fratticci A, Launay P, Clauser E, Bertagna X, Tissier F, de Reynies A & Bertherat J. Transcriptome analysis reveals that p53 and b-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Research 2010 21 8276-8281. (doi:10.1158/0008- 5472.CAN-10-2014
41. Rivlin N, Brosh R, Oren M & Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes & Cancer 2011 2 466-474. (doi:10.1177/1947601911408889
42. Raymond VM, Else T, Everett JN, Long JM, Gruber SB & Hammer GD. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2013 98 E119-E125. (doi:10.1210/jc.2012-2198
43. Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, Novokmet A, Finlay J & Malkin D. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncology 2011 12 559-567. (doi:10.1016/S1470-2045(11)70119-X)